New data for investigational gene editing program presented at EHA
CRISPR Therapeutics and Vertex share new clinical data on investigational treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting
Aiming to treat β-thalassemia and sickle cell disease with gene-edited hematopoietic stem cells
Creating the next generation of cell therapies for cancer enabled by gene editing
Jun 15, 2021
Jun 11, 2021
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
May 25, 2021
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.